Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer

JAMA

Volumn 293, Issue 19, 2005, Pages 2367-2371

  Brain, Etienne G C ^a   Bachelot, Thomas ^b   Serin, Daniel ^c   Kirscher, Sylvie ^c   Graic, Yvon ^d   Eymard, Jean Christophe ^e   Extra, Jean Marc ^f   Combe, Martin ^g   Fourme, Emmanuelle ^a   Noguès, Catherine ^a   Rouëssé, Jacques ^a  

^a Rene Huguenin Centre   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Department of Radiation Therapy   (France)

^d Hematology Department   (France)

^e INSTITUT JEAN GODINOT   (France)

^f INSTITUT CURIE   (France)

^g CENTRE HOSPITALIER DU MANS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT; TAXOID;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADULT; AGED; AMENORRHEA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CENTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIVERTICULOSIS; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA AND VOMITING; OPEN STUDY; PERITONITIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SURVIVAL RATE; BREAST TUMOR; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; SEPSIS; TAXOIDS;

EID: 20844454925     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.19.2367     Document Type: Article

References (22)

1. Jassem J, Pienkowski T, Piuzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001;19:1707-1715.
2. Nabholtz JM, Falkson C, Campos D, et al; for the TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicentre, phase III trial. J Clin Oncol. 2003;21:968-975.
3. Nowak AK, Wilcken NRC, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early-stage breast cancer. Lancet Oncol. 2004;5:372-380.
4. Cardoso F, Di Leo A, Piccart MJ. Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. Cancer Treat Rev. 2002;28:275-290.
5. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a predictive rule. J Clin Oncol. 1992;10:316-322.
6. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG study [abstract]. Proc Am Soc Clin Oncol. 2002;21:36a.
7. Bear H, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174.
8. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18:3558-3585.
9. Blay JY, Le Cesne A, Blanc-Vincent MP, Fervers B, Latour JF, Philip T. Standards, options et recommandations pour l'utilisation des facteurs de croissance en cancérologie. Presse Med. 2000;29:2004-2008.
10. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol. 2001;19:3817-3827.
11. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol. 1999;10:553-560.
12. National Cancer Institute. Common Toxicity Criteria version 2.0. Available at: http://ctep.cancer.gov/reporting/CTC-3.html. Accessed April 23, 2005.
13. Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000;355:281-283.
14. Li Z, Ibrahim NK, Wathen JK, et al. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004;101:1508-1513.
15. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19:931-942.
16. French Adjuvant Study Group. Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognosis factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001;19:602-611.
17. Martin M, Lluch A, Segui MA, et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study [abstract]. Proc Am Soc Clin Oncol. 2004;23:32.
18. Mackey JR, Cantin J, Chang S, et al. Role of hematopoietic growth factors in the prevention of neutropenic complications for breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide (TAC): results of a randomized double-blind phase III trial - BCIRG 004 [abstract]. Proc Am Soc Clin Oncol. 2001;20:10a.
19. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet. 2004;363:631-639.
20. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
21. Mamounas AP, Bryant J, Lembersky BC et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 [abstract]. Proc Am Soc Clin Oncol. 2003;22:4.
22. Fumoleau P, Bonneterre J, Luporsi E. Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol. 2003;21:1190-1191.